1. Home
  2. GENK vs AKTX Comparison

GENK vs AKTX Comparison

Compare GENK & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GEN Restaurant Group Inc.

GENK

GEN Restaurant Group Inc.

HOLD

Current Price

$1.70

Market Cap

12.8M

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$9.66

Market Cap

15.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GENK
AKTX
Founded
2011
N/A
Country
United States
United States
Employees
2700
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8M
15.4M
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
GENK
AKTX
Price
$1.70
$9.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$4.50
$33.50
AVG Volume (30 Days)
42.3K
86.6K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
1.88%
N/A
EPS Growth
62.50
N/A
EPS
N/A
N/A
Revenue
$208,380,000.00
N/A
Revenue This Year
$4.79
N/A
Revenue Next Year
$7.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.12
N/A
52 Week Low
$1.43
$0.12
52 Week High
$3.21
$29.32

Technical Indicators

Market Signals
Indicator
GENK
AKTX
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
GENK
AKTX

About GENK GEN Restaurant Group Inc.

GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: